Identification of Gene Signatures and Molecular Mechanisms for Diagnosing Parkinson’s Disease and Nonalcoholic Fatty Liver Disease Using Machine Learning
Parkinson's Disease · 2026-01 · 2026 (1)
DOI: 10.1155/padi/8731032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Parkinson's Disease, online erschienen am 26.05.2026. Verfasst von Xuan Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China, sxmu.edu.cn. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Parkinson’s disease (PD) is a prevalent neurodegenerative disease, whereas nonalcoholic fatty liver disease (NAFLD) is a common metabolic liver disorder. Growing evidence suggests that NAFLD may affect the central nervous system through the liver–brain axis, potentially contributing to PD, although the underlying molecular mechanisms remain unclear.
Methods
To identify differentially expressed genes (DEGs), transcriptomic data for NAFLD and PD were sourced from the GEO database. Key common candidate genes were screened using protein–protein interaction (PPI) networks, machine learning approaches (LASSO, neural networks, and random forest), and functional enrichment analyses, including GO, KEGG, GSEA, and GSVA. Immune infiltration, TF‐miRNA regulatory networks, and single‐cell RNA sequencing analyses were applied to investigate gene function, immune regulation, and cellular distribution. Candidate drugs were predicted using bioinformatic approaches and validated through molecular docking.
Results
CASP1, CCNA2, and INHBE were identified as three core common candidate genes that may be associated with NAFLD and PD. Involvement of these genes includes inflammatory responses, regulation of the cell cycle, metabolic pathways, and immune microenvironment remodeling. The analysis of the TF‐miRNA network suggested possible regulation by transcription factors CEBPB, BRD4, FOS, and miRNAs such as hsa‐miR‐29b‐1‐5p and hsa‐miR‐128‐3p. Drug prediction and molecular docking identified ethinyl estradiol, mesalamine, and seliciclib as candidate therapeutics, showing strong binding affinity to the core targets.
Conclusion
This study offers a comprehensive elucidation of the molecular ties between NAFLD and PD. The identified core genes and candidate drugs offer theoretical support for potential candidate biomarkers and therapeutic targets in comorbid NAFLD and PD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China, sxmu.edu.cn.
- Department of Neurology, Taiyuan City Central Hospital, Peking University First Hospital Taiyuan Branch, The Ninth Clinical Medical College of Shanxi Medical University, Taiyuan, Shanxi, China.
- Changzhi Medical College, Changzhi, Shanxi, China, czmc.com.
- School of Software, North University of China, Taiyuan, Shanxi, China, nuc.edu.cn.
ORCID-Profile: Xuan Chen, Yulin Wu, Yonglai Zhang, Yuli Hou
Zitieren
APA
Chen, X., Wu, Y., Zhang, Y., & Hou, Y. (2026). Identification of Gene Signatures and Molecular Mechanisms for Diagnosing Parkinson’s Disease and Nonalcoholic Fatty Liver Disease Using Machine Learning. Parkinson's Disease, 2026(1). https://doi.org/10.1155/padi/8731032
Vancouver
Chen X, Wu Y, Zhang Y, Hou Y. Identification of Gene Signatures and Molecular Mechanisms for Diagnosing Parkinson’s Disease and Nonalcoholic Fatty Liver Disease Using Machine Learning. Parkinson's Disease. 2026;2026(1). doi:10.1155/padi/8731032
BibTeX
@article{Chen2026,
author = {Chen, Xuan and Wu, Yulin and Zhang, Yonglai and Hou, Yuli},
title = {Identification of Gene Signatures and Molecular Mechanisms for Diagnosing Parkinson’s Disease and Nonalcoholic Fatty Liver Disease Using Machine Learning},
journal = {Parkinson's Disease},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/padi/8731032}
}
EUVIMED